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Abstract: 
Anticoagulant and antiplatelet drugs are important standard therapies used to prevent clot 
formation in the treatment and prevention of cardiovascular and cerebrovascular diseases. 
Recent advances in these therapies have seen the introduction of a number of new oral 
anticoagulant and antiplatelet drugs available in Australian clinical practice. These drugs 
although equally effective than their predecessors still may pose a risk to patients who use 
these in combination with complementary and alternative medicines (CAMs). This paper 
aims to provide an overview of the new oral anticoagulant and antiplatelet agents and 
highlight the current paucity of research which exists regarding how these agents interact 
with CAMs.  
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Introduction: 
Anticoagulants are one of the most frequently prescribed classes of medications [1]. In the 
community setting, almost 1.9 million prescriptions for warfarin were dispensed in Australia 
in 2001 with the associated cost to the Pharmaceutical Benefits Scheme (PBS) and 
Repatriation Benefits Scheme (RPBS) totalling $8.3 million [2]. Parallel with the increasing 
use of anticoagulants, associated costs including coagulation testing has also increased, 
with International Normalised Ratio (INR) testing alone accounting for 45% of procedural 
treatments for all cardiac conditions in Australia in 2007-08 [3].  
 
For almost 70 years vitamin K antagonists (VKA) and heparins have been the mainstay 
anticoagulants for the treatment and prevention of thrombosis [4]. Heparins are best suited 
for short term prevention and initial treatment of venous thromboembolism (VTE) or arterial 
occlusion whereas VKAs such as warfarin, used for atrial fibrillation (AF) and patients with 
mechanical heart values, have been the mainstay of long term anticoagulation therapy [5].  
 
Similarly antiplatelet therapy with the use of drugs such as aspirin has risen markedly in 
Australia since the late 1990s [3]. Aspirin, which has long been the bedrock of antiplatelet 
therapy in patients with acute coronary syndromes (ACS) [6], is one of the most widely 
used medical treatments worldwide with millions of patients taking low-dose aspirin on a 
daily basis [7]. Clopidogrel, a newer antiplatelet agent listed on the PBS since 2009, is a 
more potent platelet inhibitor than aspirin and has been shown to be more effective in ACS 
when combined with aspirin when compared with aspirin therapy alone [8, 9].   
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Antiplatelet and anticoagulant therapies, whilst highly effective, have well known limitations 
including increased risk of bleeding, adverse drug events and increased readmission rates 
[10, 11]. Other challenges from the perspective of the prescribing physician and patient 
also exist. Heparins require injection or infusion. Warfarin has a narrow therapeutic index 
window, variable dose response and multiple interactions with other drugs, foods and 
concurrent illnesses, and there is a need for frequent laboratory monitoring of dose-effect 
[5, 12]. Antiplatelet agents are limited by bleeding complications, most of which arise from 
the upper gastrointestinal tract [9, 13] as well as a number of drug interactions [14]. 
Furthermore, the antiplatelet action of clopidogrel is reliant on hepatic activation of the 
drug, resulting in relatively low onset of action and delayed antithrombotic effect. 
“Clopidogrel resistance” is also a limitation in antiplatelet therapy for some patients which is 
a phenomenon characterised by significant interpatient variability in plasma concentrations 
of active drug and pharmacologic outcomes [15]. 
 
Moreover these therapies, particularly warfarin, also have known potential interactions with 
food and complementary and alternative medicines (CAMs) [16-18] which, as defined by 
the Australian Medical Association (AMA), include a wide range of products and treatments 
with therapeutic claims that are not presently considered to be part of conventional 
medicine [19]. In Australia CAM use is substantial with more than two-thirds of the 
Australian adult population using at least one form of CAM [20], often in conjunction with 
conventional medicines and with failure to report CAM use to their doctor [20, 21]. CAM-
drug interactions are significant given the adverse patient safety risks that may arise.  
 
Recent developments in anticoagulation and antiplatelet therapy have resulted in a number 
of new therapies introduced into clinical practice with properties that overcome the practical 
limitations of their predecessors [22]. Three anticoagulants and two antiplatelets now have 
Therapeutic Goods Administration (TGA) approval for use in Australia and are listed on the 
PBS for subsidy. Subsequently, warfarin prescriptions have reduced by more than half 
(~861,000) when compared to 2001 data [23].  
 
The purpose of this article is to provide context to why antithrombotic-CAM interactions 
should form an important consideration in Australian healthcare, a simple overview of the 
new antiplatelet and anticoagulant agents available, mechanisms of action, clinical 
indications, interactions and known interactions with CAM, of which there are few, to 
improve knowledge of potential interactions for all health professionals.   
 
The importance of CAM in Australian Clinical Practice 
In Australia CAM, a diverse group of health care practices and therapies not considered 
part of conventional medicine [19], forms a considerable component of the healthcare 
industry [20] despite its exclusion from the government-funded health system. Australian 
studies have suggested that visits to medical and CAM practitioners are identical, that 
Australians have more out-of-pocket expenditure on CAM than conventional medicine [20], 
and in some regions of Australia, CAM practitioners may be present in numbers equal to 
conventional primary care providers [24].  
 
Parallel with increasing CAM utilisation, considerable focus been placed on CAM-drug 
interactions which can impact on the pharmacokinetics and/or pharmacodynamics leading 
to potential serious patients safety risks [25-30]. Research suggests that 3.7 million 
Australians may be at risk of CAM-drug interactions due to concurrent use of CAM and 
pharmaceutical drugs [31]. Concomitant CAM-drug use is further compounded by the 
general public’s belief that CAM, particularly herbal medicines, are considered safe 
because they are natural [32], and limited dialogue about CAM use between patients and 
health care providers [20, 21, 33, 34]. CAMs that may interfere with the effect of 
anticoagulant or antiplatelet therapy are of particular concern considering the prevalence of 
these therapies for the treatment of cardiovascular disease. 
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A number of drug-herb interactions involving antiplatelet or anticoagulant drugs have been 
published with the majority of interactions identified to date involving drugs with a narrow 
therapeutic index, such as with warfarin. This has significant implications particularly in pre- 
or post-operative patients, patients with clotting disorders, those on anticoagulant therapy, 
and the elderly [35]. Elderly patients pose significant risk due to polypharmacy and 
polyherbacy issues [36, 37]. A study of 3070 elderly people found that almost three 
quarters of participants (74.2%) used at least one prescription drug and one dietary 
supplement and nearly one third (32.5%) used three or more prescription drugs and three 
or more supplements [37].  
 
Due to the substantial use of anticoagulant and antiplatelet medicines in Australian clinical 
practice and recent inclusions of a number of new antithrombotic agents, a low disclosure 
of CAM use, polyherbacy, and the risk of patient safety adverse events occurring due to 
interactions in vulnerable groups, this paper provides a timely update for all healthcare 
professionals to increase awareness in an area which has known patient safety 
implications which could be largely preventable.   
 
New Oral Anticoagulants (NOACs) 
 
Pharmacology 
Dabigatran (Pradxa®)  
Dabigatran etexilate is the pro-drug of dabigatran, which selectively and reversibly inhibits 
both free and clot-bound thrombin by binding to the active site of thrombin molecule [1, 38]. 
As a prodrug, dabigatran etexilate is cleaved by a hydrolytic reaction involving serum and 
liver serine esterases to the active form [38]. This reaction occurs rapidly after intestinal 
absorption with peak plasma dabigatran concentrations occurring approximately 0.5 – 2 
hours after oral ingestion. Dabigatran has a half-life of 12-14 hours [1, 4, 22, 39] and given 
its hydrophilic nature has a poor intestinal absorption and a low oral bioavailability of 6.5% 
[38]. Dabigatran is unique in that it is not metabolised, induced or inhibited by the 
cytochrome P450 (CYP450) drug metabolising enzymes [1]. Dabigatran is a substrate for 
the p-glycoprotein (P-gp) efflux reverse transporter, an ATP-dependant pump that 
transports numerous substrates, including drugs across cell membranes [38]. Elimination 
of dabigatran after hepatic activation occurs predominately in the kidneys (up to 80%) [12].  
 
Rivaroxaban (Xarelto®) 
Rivoraxaban is a direct and competitive active site factor Xa inhibitor which achieves 
maximum plasma levels approximately 3 hours after oral ingestion. The bioavailability of 
rivaroxaban is between 80 and 100% and has a half-life of approximately 5-9 hours, which 
is increased to 11-13hrs for individuals greater than 75 years of age [12, 38] . Rivaroxaban 
is metabolised by CYP3A4 in the CYP450 system with 70% of the drug excreted in the 
urine and the remaining 30% excreted through the faeces [1, 38]. Rivaroxaban does 
interact with the CY450 system with specific interactions with CYP3A4 and CYP2J2 [40]. 
Similar to dabigatran, rivaroxaban is a substrate for P-gp efflux transport, but unlike 
dabigatran it is metabolised in the liver [1, 38].   
 
Apixaban (Eliquis®) 
Apixaban is a direct inhibitor of factor Xa that inhibits both free and fibrin-bound factor Xa 
and activated prothrombinase and acts independently of endogenous antithrombin [41]. 
With a bioavailability of more than 50%, Apixaban reaches peak plasma concentration in 3 
hours and has a variable half-life dependant on the dosing frequency; 8-11 hours when 
administered twice daily and 12-15 hour when given once daily [38]. This agent is 
metabolised by CYP3A4 in the CYP450 system and the route of elimination is 30% renal 
and 70% faecal. Apixaban showed moderate selectivity for clot-bound over free factor Xa 
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and also inhibits thrombin generation. Apixaban has minimal interaction through the p-
glycoprotein transporter system [1]. 
 
Clinical Indications and Dosing 
In Australia Apixiaban, dabigatran and rivaroxaban are approved for prevention of venous 
VTE in adult patients who have undergone major orthopaedic surgery (total hip 
replacement [36] or total knee replacement (TKR). They are also indicated for the 
prevention of stroke and systemic embolism in patients with non-valvular AF. Rivaroxaban 
also is indicated for treatment of deep vein thrombosis (DVT), pulmonary embolism (PE) 
and prevention of recurrent DVT and PE. All three are contraindicated in pregnancy and 
breastfeeding as safety has not yet been established. Their lack of reversibility is largely 
documented in the literature, however this is not uncommon for other anticoagulant agents 
such as low-molecular-weight-heparins (LMWHs) and pentasaccharides [42]. Dosages for 
the NOACs are provided in Table 1 below [39, 43, 44].  
 
Table 1: Indication dosing for NOAC  
Indication Apixaban Rivaroxaban Dabigatran 
AF 
5mg orally daily 
 
2.5mg orally twice daily for 
patients with at least two 
of the following 
characteristic: age >80, 
weight <60kg, SCr 
>133mircromol/L 
20mg orally daily 
 
15mg orally daily for 
patients with CrCl 30-
49mL/min 
150mg orally twice daily 
 
110mg orally twice daily for 
patients with CrCl 30-
50mL/min 
 
110mg orally twice daily for 
patients >75 years old.  
DVT/PE N/A 
15mg orally twice daily for 
3 weeks, then 20mg orally 
daily thereafter 
N/A 
VTE 
Prophylaxis 
2.5mg orally twice daily 
 
10-14 days for TKR, 32-38 
days for THR 
10mg orally daily 
 
14 days for TKR, 35 days 
for THR 
110mg orally 1-4 hours of 
surgery then 220mg daily 
 
10 days for TKR, 28-35 days 
for THR 
 
150mg orally daily for 
patients with CrCl 30-
50mL/min 
 
AF, Atrial Fibrillation; DVT, Deep Vein Thrombosis; PE, Pulmonary Embolism; VTE, Venous 
thromboembolism 
 
 
Interactions  
As with other anticoagulants, drugs that increase the risk of bleeding should be used with 
caution and co-administration of other anticoagulants is contraindicated with rivaroxaban, 
apixaban and dabigatran [41]. However, bleeding rates have been found to be generally 
lower with NOACs compared with warfarin therapy, with intracranial haemorrhage rates 
reduced by at least 50% [42].  
 
Despite high expectations of less food interactions with NOAC therapies, consideration of 
pharmacokinetic effects of accompanying drugs and CAM, particularly herbal medicines, 
must be considered by physicians when prescribing NOACs as well other health 
professionals involved in the patients’ care. The metabolic route of the NOACs raises 
concerns for potential interactions with other drugs and CAMs that are involved with the 
CYP450 enzyme system or P-gp transporters. The currently acknowledged drug and CAM 
interactions as well as the potential impact these interactions may among the general 
population is listed in Table 2.     
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Table 2 –  Drug and CAM Interactions with NOACs (adapted from [38, 41, 45].  
  
Drug Interactions 
 
CAM Interactions Population at risk 
Apixaban Antiplatelet agents 
- Clopidogrel 
Not reported Cardiovascular disease 
 
Dabigatran CYP3A4 and P-gp inhibitors: 
- Clarithromycin 
- Cyclosporin 
- Tacrolimus 
- Itraconazole 
 
P-gp inhibitors: 
- Quinidine 
- Amiodarone 
- Verapamil 
- Tacrolimus 
 
CYP3A4 and P-gp inducers: 
- Rifampicin 
- Pantoprazole 
- Carbamazepine 
 
NSAIDs: 
- Aspirin 
- Naproxen 
- Diclofenac 
 
Antiplatelet agents: 
- Clopidogrel 
- Ticagrelor  
 
Protease inhibitors: 
- Ritonavir (limited clinical data) 
 
 
 
 
 
 
 
 
CYP3A4 and P-gp inducers: 
- St John’s Wort 
Cardiac arrhythmias 
Minor depression 
Bacterial infections including 
pharyngitis, tonsillitis, MRSA, 
TB, meningococcus 
Malaria 
Cluster headaches 
Gastro-oesophageal reflux 
disease 
Previous gastrointestinal 
haemorrhage in last 12 months  
Cardiovascular disease 
Pain, fever and inflammation 
including arthritis 
Elderly people 
Liver disease 
Renal impairment 
 
Rivaroxaban CYP3A4 and P-gp inhibitors: 
- Ketoconazole  
- Itraconazole 
- Voriconazole 
- Posaconazole 
- Ritonavir 
- Clarithromycin 
- Dronedarone (limited clinical 
data) 
 
CYP3A4 and P-gp inducers: 
- Rifampicin 
- Phenytoin 
- Carbamazepine 
- Phenobaribitone 
 
NSAIDs 
- Aspirin 
- Naproxen 
 
Antiplatelet agents 
- Clopidogrel 
 
 
 
 
 
 
 
 
CYP3A4 and P-gp inducers: 
- St John’s Wort 
HIV and AIDS 
Minor depression 
Fungal infections 
Bacterial infections including 
pharyngitis, tonsillitis, MRSA, 
TB, meningococcus 
Respiratory tract infections 
Epilepsy and bipolar disorder 
Cardiovascular disease 
Pain, fever and inflammation 
including arthritis 
Elderly people 
Liver disease 
Renal impairment 
 
AIDS, acquired immune deficiency syndrome; CYP3A4, Cytochrome P450 family 3, subfamily A; CYP450, Cytochrome 
P450; HIV, human immune deficiency virus; MRSA, methicillin-resistant Staphylococcus aureus; NSAIDS, non-steroidal 
anti-inflammatory drugs; TB, tuberculosis. 
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New Oral Antiplatelets (NOAPS) 
 
Pharmacology 
Prasugrel (Effient®) 
Prasugrel, a third generation thienopyridine, is a prodrug whose active metabolite R-
138727 specifically and irreversibly binds to the P2Y12 receptor inhibiting ADP mediated 
platelet activation and aggregation [46]. Following inactivation by metabolism, which occurs 
primarily by CYP3A and CYP2B6, prasugrel active metabolite and other metabolites are 
excreted in the urine (70%) and faeces (30%). On oral administration, prasugrel has a 
rapid and nearly complete (>80%) gastrointestinal absorption, with peak maximal platelet 
inhibition occurring within 1 hour and a half-life of 7 hours [47, 48]. Preclinical and clinical 
studies have revealed that prasugrel has been demonstrated to have a faster onset of 
action, increased potency and less response variability with respect to platelet inhibitory 
activity as compared with clopidogrel [44] 
 
Ticagrelor (Brillinta®) 
Ticagrelor is an orally administered nonthienopyridine, which directly and reversibly inhibits 
the P2Y12 receptor. It is an ATP analogue that binds reversibly in a non-competitive manner 
to the P2Y12 receptor at distinct sites to ADP and the thienopyridines. Ticagrelor binds 
directly to and changes the conformation of the P2Y12 receptor and therefore results in a 
reversible inhibition of the receptor. Ticagrelor is rapidly metabolised by hepatic 
CYP3A4/CYP3A5, however does not require metabolic activation to achieve its antiplatelet 
activity as both the parent drug and active metabolite exhibit antiplatelet activity. With a 
bioavailability of about 40% and 7 hour half-life, ticagrelor reaches maximal platelet 
inhibition within 2 hours of dosing and is excreted largely through the faeces and has a 
maximal platelet inhibition  [47, 48].  
 
Clinical Indications and Dosing 
In Australia, prasugrel is approved as an alternative to clopidogrel for treating acute 
coronary syndrome (moderate to high risk unstable angina, ST-segment-elevation 
myocardial infarction [STEMI] or non-ST-segment-elevation myocardial infarction 
(NSTEMI) in combination with aspirin in patients who undergo a percutaneous coronary 
investigation (PCI). Prasugrel has a more rapid and potent effect on platelet inhibition in 
comparison to clopidogrel which results in a greater reduction in the risk of atherothrombic 
events, mainly non-fatal myocardial infarction (MI), but at the expense of increased risk of 
bleeding. Because of the bleeding risk, prasugrel should be used with caution in people 
with low body weight (<60kg), the elderly (>75years), patients undergoing or possibly 
requiring urgent coronary artery bypass grafting (CABG) during therapy, patients with renal 
impairment (particularly end stage renal disease), and those receiving other treatments, or 
with coexisting conditions, that make them more prone to bleeding [49].  
 
Ticagrelor is approved for the prevention of atherothombotic events in acute coronary 
syndrome (MI or unstable angina) in combination with aspirin. Current Australian 
guidelines recommend treatment with aspirin and clopidogrel for up to 12 months after a 
STEMI. However NOAPs can be considered if a patient is undergoing PCI and is at high 
risk of another ischaemic event (e.g. diabetic patients, stent thrombosis) although the risk 
of bleeding needs to be carefully assessed. In patients with high risk non-ST-segment-
elevation acute coronary syndromes (NSTEACS) and at low risk of bleeding, current 
Australian guidelines recommend patients be treated with NOAPs. Ticagrelor should be 
avoided in patients at higher risk of bleeding and used in caution in patients with a history 
of dyspnoea or bradycardia, asthma, chronic obstructive pulmonary disease (COPD) or 
heart failure [50, 51]. Dosages for ticagrelor and prasugrel are provided in Table 3 [49, 50] .    
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Table 3: NOAP Dosing  
Dose  Prasugrel Ticagrelor  
Dose 
60mg orally – loading dose  
 
10mg orally once daily – maintenance 
dose 
 
Should be taken combined with low 
dose aspirin (75-150mg daily) 
 
180mg orally – loading dose 
 
90mg orally twice daily – maintenance dose 
 
Must be combined with low dose aspirin (75-
110mg daily) 
Dose 
adjustment 
No dosage adjustment required for 
renal impairment or in mild/moderate 
hepatic impairment 
 
Lower maintenance dose for people 
<60kg or >75 years old – 5mg orally 
once daily due to increased risk of 
bleeding.  
 
N/A 
 
 
Interactions  
Prasugrel does not appear to interact to any clinically relevant extent with other drugs or 
CAMs including those metabolised by CYP450 enzymes [52]. However as the drugs profile 
continues to develop, emerging research suggests that interactions may exist e.g. ritonavir 
interaction [53].  
 
Comparatively, ticagrelor has a number of known interactions. CYP3A4 inhibitors may 
increase the risk of bleeding in patients taking ticagrelor and therefore strong CYP3A4 
inhibitors (e.g. ketoconazole, clarithromycin) should not be used concomitantly and 
moderate CYP3A4 inhibitors (e.g. verapamil, erythromycin, fluconazole) should be used 
with caution. Ticagrelor use with CYP3A4 inducers may decrease its efficacy therefore use 
cautiously with concomitant use. Ticagrelor also weakly inhibits P-gp and monitoring for 
adverse effects is particularly important if the substrate has a narrow therapeutic range e.g. 
tacrolimus. Ticagrelor use should also be avoided in patients taking doses of simvastatin 
>40mg/day as this may increase the risk of myopathy and rhabdomyolysis [54, 55]. 
Grapefruit juice has also been found to increase concentration of ticagrelor and the risk of 
bleeding [56].  
 
Conclusions 
As the NOACs and NOAPs, which offer more specific and reliable pharmacological 
properties to their predecessors, continue to be implemented in Australian clinical practice, 
further understanding of their clinical profiles will undoubtedly become available. While to 
date few drug and CAM interactions have been reported as highlighted through this review, 
it is still early in their development and clinical use cycle, particularly in the Australian 
population. Limited understanding of CAM with NOACs and NOAPs is of significant 
importance, particularly when one considers the current safety landscape of CAM.  
 
In Australia, CAM is largely unregulated and therefore may not be monitored by safety 
mechanisms and reporting systems incorporated into mainstream regulatory and legislative 
frameworks or well utilised by CAM practitioners who may have limited knowledge that 
these exist. This, coupled with the paucity in the literature surrounding CAM and NOAC 
and NOAP use in clinical practice may have significant implications on patient safety and 
must be considered, well documented and communicated to all members of the healthcare 
team who care for these patients.  
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Furthermore CAM-NOAC and CAM-NOAP interactions are of significant importance due to 
the significant proportion of Australian patients who utilise CAM as a component of their 
healthcare and the potential for serious interactions and subsequent negative patient 
safety outcomes. CAM-NOAP and CAM-NOAC interactions are further impacted by lack of 
communication and subsequent disclosure of CAM use by patients as well as a high rate of 
concomitant CAM use with pharmaceutical medicines.  
 
Interprofessional communication between conventional and CAM providers therefore is 
essential in ensuring the appropriate and safe management of patients particularly in those 
using NOACs and NOAPs. Despite positive attitudes and support towards interprofessional 
communication [57-59] low rates of interprofessional communication are reported to exist. 
Efforts to improve teamwork and communication between the disciplines must build upon 
shared values and practice methods that support the creation of a patient safety culture, 
however may not necessitate the ‘reinvention of the wheel’ [57].  
 
Finally, the CAM in the context of medical education is poorly developed in Australia with 
much of the onus resting on the individual medical practitioner to acquire knowledge 
regarding CAM in the clinical setting [60] Lack of CAM education by medical practitioners 
coupled with an increased utilisation of CAM by the Australian population further enhances 
the risk of polypharmacy issues, particularly as the clinical profile of such drugs as NOACs 
and NOAPs continues to develop.   
 
This review is timely considering the increased profile of antithrombotic medicines 
discussed in this review and their extensive use throughout the Australian population. As 
the interaction profile of NOACs and NOAPs with CAM continues to develop with increased 
clinical use, it is a timely reminder for health professionals to support their patients to 
benefit from all forms of healthcare without increasing the risk of iatrogenic complications. 
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